Production Method 1

147702-16-7

871130-17-5

Reaction Conditions

1.1 Reagents: Pyridine ,  Phosphorus oxychloride Solvents: Pyridine ;  25 °C; 6 h, 25 °C
1.2 Reagents: Water ;  25 °C; 2 h, 25 °C

Reference

New derivatives of VAPOL and VANOL: structurally distinct vaulted chiral ligands and Bronsted acid catalysts

Desai, Aman A.; et al, Synthesis, 2010, (21), 3670-3680

Production Method 2

147702-15-6

871130-17-5

Reaction Conditions

Reference

Bronsted acid-catalyzed imine amidation

Rowland, Gerald B.; et al, Journal of the American Chemical Society, 2005, 127(45), 15696-15697

Diphenanthro[4,3-d:3',4'-f][1,3,2]dioxaphosphepin,18-hydroxy-8,9-diphenyl-, 18-oxide, (8aS)- Raw materials

• [3,3'-Biphenanthrene]-4,4'-diol,2,2'-diphenyl-, (3S)-
• [3,3'-Biphenanthrene]-4,4'-diol,2,2'-diphenyl-, (3R)-

Diphenanthro[4,3-d:3',4'-f][1,3,2]dioxaphosphepin,18-hydroxy-8,9-diphenyl-, 18-oxide, (8aS)- Preparation Products

• Diphenanthro[4,3-d:3',4'-f][1,3,2]dioxaphosphepin,18-hydroxy-8,9-diphenyl-, 18-oxide, (8aS)- (871130-17-5)

• 1. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 2. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

Recent Advances in the Study of Diphenanthro[4,3-d:3',4'-f][1,3,2]dioxaphosphepin,18-hydroxy-8,9-diphenyl-, 18-oxide, (8aS)- (CAS: 871130-17-5)

The compound Diphenanthro[4,3-d:3',4'-f][1,3,2]dioxaphosphepin,18-hydroxy-8,9-diphenyl-, 18-oxide, (8aS)- (CAS: 871130-17-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic phosphorus-containing molecule exhibits unique structural and electronic properties, making it a promising candidate for various applications, including catalysis, material science, and drug development. Recent studies have focused on elucidating its synthesis, reactivity, and potential biological activities.

One of the key breakthroughs in the synthesis of this compound involves the use of stereoselective methods to achieve the (8aS)- configuration, which is critical for its biological activity. Researchers have optimized reaction conditions to improve yield and purity, leveraging advanced spectroscopic techniques such as NMR and X-ray crystallography for structural confirmation. The compound's stability under physiological conditions has also been investigated, providing insights into its potential as a therapeutic agent.

In terms of biological activity, preliminary studies suggest that Diphenanthro[4,3-d:3',4'-f][1,3,2]dioxaphosphepin derivatives exhibit inhibitory effects on specific enzymes involved in inflammatory pathways. For instance, in vitro assays have demonstrated its ability to modulate the activity of phosphodiesterases (PDEs), which are implicated in various diseases, including cancer and neurodegenerative disorders. These findings highlight the compound's potential as a lead structure for the development of novel PDE inhibitors.

Further research has explored the compound's mechanism of action at the molecular level. Computational modeling and molecular docking studies have revealed its high affinity for the active sites of target enzymes, providing a rationale for its observed bioactivity. Additionally, structure-activity relationship (SAR) studies have identified key functional groups that contribute to its potency and selectivity, offering valuable guidance for future medicinal chemistry efforts.

Despite these promising results, challenges remain in translating these findings into clinical applications. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through comprehensive preclinical studies. Recent efforts have focused on derivatization strategies to enhance the compound's pharmacokinetic properties while maintaining its therapeutic efficacy.

In conclusion, Diphenanthro[4,3-d:3',4'-f][1,3,2]dioxaphosphepin,18-hydroxy-8,9-diphenyl-, 18-oxide, (8aS)- represents a fascinating area of research with significant potential for drug discovery and development. Continued interdisciplinary collaboration between chemists, biologists, and pharmacologists will be essential to unlock its full therapeutic potential and address the remaining challenges in its development.

• 878111-18-3((S)-4-oxide-4-hydroxy-2,6-bis(2,4,6-trimethylphenyl)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin)
• 175223-61-7((S)-VANOL Hydrogen Phosphate)
• 66485-93-6(Phosphoric acid, [1,1'-biphenyl]-2-yl bis(dimethylphenyl) ester)
• 695162-87-9((R)-4-oxide-4-hydroxy-2,6-bis(2,4,6-trimethylphenyl)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin)
• 791616-57-4
• 956610-76-7(R-Vanol hydrogenphosphate)
• 112921-32-1(Dibenzo[d,f][1,3,2]dioxaphosphepin, 6-methoxy-1,11-dimethyl-, 6-oxide, (±)-)
• 66485-94-7(Phosphoric acid, [1,1'-biphenyl]yl dimethylphenyl methylphenyl ester)
• 644990-13-6(PHOSPHORIC ACID, BIS[4'-[(DIPHENOXYPHOSPHINYL)OXY][1,1'-BIPHENYL]-4-YL]PHENYL ESTER)
• 871130-18-6((R)-(–)-VAPOL hydrogenphosphate)